ReviewNuclear medicine communications2025
The evolution and hotspots of radioactive iodine therapy in hyperthyroidism: a bibliometric analysis.
Review in Nuclear medicine communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveHyperthyroidism, a prevalent endocrine disorder, disrupts metabolic balance and cardiovascular health, affecting millions globally. Radioactive iodine (RAI), a treatment for hyperthyroidism, employs high-energy beta particles to reduce thyroid tissue, lowering volume and hormone levels. This study utilizes bibliometric analysis to outline RAI's evolution and identify hotspots in hyperthyroidism treatment.
methodsA total of 2904 articles and reviews published between 1981 and 2023 were retrieved from the Web of Science Core Collection using the research strategy. Bibliometric analyses, employing VOSviewer and CiteSpace, were performed to visualize the cooperation network, evolution, and hot topics.
resultsAnnual publications rose in waves, 2904 papers from 2564 institutions, and 84 countries. The USA led, contributing the largest share, with the journal Thyroid dominating publication. The University of Pisa contributed the most articles. Co-occurrence analysis classified keywords into five clusters: treatment mechanism, safety, effectiveness assessment, individualized radioactive dosage, and management. The development of RAI therapy for hyperthyroidism can be divided into three stages: safety and efficacy assessment, personalized treatment plans, and treatment of drug-resistant and surgery-resistant hyperthyroidism.
conclusionAttention to RAI in hyperthyroidism should be significantly increased. It is necessary to establish collaborations between authors, countries, and institutions to promote the development of this field. Recent research has focused on personalized radioactive dosage formulation and follow-up. Future studies are likely to concentrate on drug-resistant and surgery-resistant hyperthyroidism, which is also worthy of investigation. These findings provide a new perspective on the study of RAI in hyperthyroidism, potentially contributing to the improvement of the quality of life for patients with hyperthyroidism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.